You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 24, 2024

BREYNA Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Breyna patents expire, and what generic alternatives are available?

Breyna is a drug marketed by Mylan and is included in one NDA.

The generic ingredient in BREYNA is budesonide; formoterol fumarate dihydrate. There are twenty-two drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the budesonide; formoterol fumarate dihydrate profile page.

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for BREYNA?
  • What are the global sales for BREYNA?
  • What is Average Wholesale Price for BREYNA?
Summary for BREYNA
Drug patent expirations by year for BREYNA
Drug Prices for BREYNA

See drug prices for BREYNA

US Patents and Regulatory Information for BREYNA

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Mylan BREYNA budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 211699-001 Mar 15, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Mylan BREYNA budesonide; formoterol fumarate dihydrate AEROSOL, METERED;INHALATION 211699-002 Mar 15, 2022 AB RX No No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

EU/EMA Drug Approvals for BREYNA

Company Drugname Inn Product Number / Indication Status Generic Biosimilar Orphan Marketing Authorisation Marketing Refusal
Teva Pharma B.V.  Budesonide/Formoterol Teva Pharma B.V. budesonide, formoterol fumarate dihydrate EMEA/H/C/004882
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate:-in patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.or-in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists.COPDSymptomatic treatment of patients with COPD with forced expiratory volume in 1 second (FEV1) 
Authorised no no no 2020-04-03
Teva Pharma B.V. Budesonide/Formoterol Teva Pharma B.V. budesonide, formoterol fumarate dihydrate EMEA/H/C/003953
Budesonide/Formoterol Teva Pharma B.V. is indicated in adults 18 years of age and older only.AsthmaBudesonide/Formoterol Teva Pharma B.V. is indicated in the regular treatment of asthma, where use of a combination (inhaled corticosteroid and long-acting β2 adrenoceptor agonist) is appropriate: orin patients not adequately controlled with inhaled corticosteroids and “as needed” inhaled short-acting β2 adrenoceptor agonists.in patients already adequately controlled on both inhaled corticosteroids and long-acting β2 adrenoceptor agonists. 
Withdrawn no no no 2014-11-19
>Company >Drugname >Inn >Product Number / Indication >Status >Generic >Biosimilar >Orphan >Marketing Authorisation >Marketing Refusal

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.